A survival score based on symptoms and performance status for patients with high-grade gliomas receiving radiochemotherapy

Pham Cam Phuong, Le Viet Nam, Steven E. Schild, Dirk Rades, Mai Trong Khoa

Research output: Contribution to journalArticle

Abstract

Aim: To create a simple survival score for patients with high-grade gliomas based on clinical symptoms and performance status. Patients and Methods: Thirty-six patients received neurosurgical intervention followed by radiochemotherapy for high-grade gliomas. Six pre-treatment symptoms were included in the score depending on their impairment of quality of life, scoring each between 1 and 3. For each patient, the points from the symptoms were added and another 4 points were added for Karnofsky performance status (KPS) <80%. Based on the survival rates of these scores, two groups were formed: 1-4 (group A) and 5-12 points (group B). Results: The 1-, 2- and 3-year survival rates in group A were 100%, 33% and 24% in group A and 47%, 7% and 0% in group B (p<0.001). In addition, complete tumor resection (p<0.001) and tumor grade III (p<0.001) were associated with improved survival. Conclusion: A simple survival score was developed helping physicians in decisionmaking for patients with high-grade gliomas.

Original languageEnglish (US)
Pages (from-to)689-693
Number of pages5
JournalIn Vivo
Volume31
Issue number4
DOIs
StatePublished - Jul 1 2017

Keywords

  • Clinical symptoms
  • High-grade gliomas
  • Performance status
  • Radiochemotherapy
  • Survival score
  • Temozolomide

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'A survival score based on symptoms and performance status for patients with high-grade gliomas receiving radiochemotherapy'. Together they form a unique fingerprint.

  • Cite this